and 94.4%, respectively) in Henan Province were higher than the average levels (10.2%, 62.5%, respectively) reported by a worldwide study (*10*). Pyrazinamide is an essential drug recommended by World Health Organization guidelines for treatment of MDR TB. Among the population with MDR TB that we studied, 10 (76.9%) of 13 XDR isolates were sensitive to pyrazinamide (data not shown), suggesting that pyrazinamide is still an effective first-line anti-TB drug for most XDR TB patients in Henan Province.

We restricted our investigation to 1 province. However, given the average national prevalence of XDR TB (8% of MDR TB) (*1*) and the magnitude of the population of Henan Province, our findings indicate that the prevalence of XDR TB might be higher in central China than previously documented.

Dawei Shi, Hui Li, Yuling Zhao, Qiong Jia, Christopher Coulter, Liang Li,[1] and Guofeng Zhu[1]

Author affiliations: Institute of Pathogen Biology of Chinese Academy of Medical Sciences, Beijing, China (D. Shi, Q. Jia, G. Zhu); Peking Union Medical College, Beijing (D. Shi, Q. Jia, G. Zhu); National Institute for the Control of Pharmaceutical and Biological Products, Beijing (D. Shi); Henan Provincial Centers for Disease Control and Prevention, Zhengzhou, China (H. Li, Y. Zhao); Pathology Queensland, Brisbane, Queensland, Australia (C. Coulter); and Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing (L. Li)

[1]These authors contributed equally to this article.

References

1. Zhao Y, Xu SF, Wang LX, Chin DP, Wang SF, Jiang GL, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med. 2012;366:2161–70. http://dx.doi.org/10.1056/NEJMoa1108789
2. He GX, Zhao YL, Jiang GL, Liu YH, Xia H, Wang SF, et al. Prevalence of tuberculosis drug resistance in 10 provinces of China. BMC Infect Dis. 2008;8:166. http://dx.doi.org/10.1186/1471-2334-8-166
3. Deng Y, Wang Y, Wang J, Jing H, Yu C, Wang H, et al. Laboratory-based surveillance of extensively drug-resistant tuberculosis, China. Emerg Infect Dis. 2011;17:495–7.
4. Sun Z, Chao Y, Zhang X, Zhang J, Li Y, Qiu Y, et al. Characterization of extensively drug-resistant *Mycobacterium tuberculosis* clinical isolates in China. J Clin Microbiol. 2008;46:4075–7. http://dx.doi.org/10.1128/JCM.00822-08
5. Tang S, Zhang Q, Yu J, Liu Y, Sha W, Sun H, et al. Extensively drug-resistant tuberculosis, China. Emerg Infect Dis. 2011;17:558–60.
6. Wang D, Yang C, Kuang T, Lei H, Meng X, Tong A, et al. Prevalence of multidrug and extensively drug-resistant tuberculosis in Beijing, China: a hospital-based retrospective study. Jpn J Infect Dis. 2010;63:368–71.
7. Zhao M, Li X, Xu P, Shen X, Gui X, Wang L, et al. Transmission of MDR and XDR tuberculosis in Shanghai, China. PLoS ONE. 2009;4:e4370. http://dx.doi.org/10.1371/journal.pone.0004370
8. Shi D, Li L, Zhao Y, Jia Q, Li H, Coulter C, et al. Characteristics of *embB* mutations in multidrug-resistant *Mycobacterium tuberculosis* isolates in Henan, China. J Antimicrob Chemother. 2011;66:2240–7. http://dx.doi.org/10.1093/jac/dkr284
9. World Health Organization. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs.WHO/HTM/TB/2008.392. Geneva: The Organization; 2008.
10. Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, Martin-Casabona N, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis. 2007;13:380–7. http://dx.doi.org/10.3201/eid1303.061400

Address for correspondence: Guofeng Zhu, No.6 Rong Jing Dong Jie, Beijing Economic-Technological Development Area, Beijing 100176, China; email: zhugf@yahoo.com

Seroprevalence of Pandemic Influenza Viruses, New York, New York, USA, 2004

To the Editor: Exposures to influenza viruses can lead to immune responses that substantially affect susceptibility to infection with related viruses. Characterization of preexisting immunity within a population can inform public health, as highlighted during the influenza A(H1N1)pdm09 virus pandemic, when surveillance data demonstrated that older persons (≥65 years old) were less likely than younger persons to have influenza (*1*). Seroprevalence studies of prepandemic samples show that older persons had preexisting antibody responses to A(H1N1)pdm09 virus, presumably because of prior exposure to related strains (*2*). The A(H1N1)pdm09 virus possesses hemagglutinin and neuraminidase genes derived from classical swine influenza virus (*3*).

Epidemiologic and molecular data indicate that prior exposure to early twentieth century H1N1 viruses conferred immunity to A(H1N1)pdm09 virus. Human antibodies that neutralize A(H1N1)pdm09 virus and H1N1 subtype viruses from earlier in the twentieth century have been characterized, and animal studies have demonstrated that antibodies to the earlier H1N1 subtype viruses cross-neutralize A(H1N1)pdm09 virus and protect from virus challenge (*2,4–6*). Prior exposure to antigenically related viruses can explain the relationship between age and susceptibility to infection.

To determine the seroprevalence of preexisting hemagglutinin inhibition (HAI) antibody titers to influenza strains with pandemic potential, we tested serum samples for antibodies to A(H1N1)pdm09 virus and the 1918, 1957, and 1968 pandemic viruses.

The samples had been collected in 2004 from a representative sample of adults in New York City (NYC), USA, as part of the NYC Health and Nutrition Examination Survey (online Technical Appendix, wwwnc.cdc.gov/EID/pdfs/12-0156-Techapp.pdf). For the 1918 and A(H1N1)pdm09 viruses, the highest prevalence of HAI titers >40 was among persons born before 1940 (>65 years old in 2004), although younger adults also had antibodies. Antibody prevalence to the 1957 H2N2 subtype virus was highest among persons born during 1942–1961, and >70% in persons born before 1971 had antibody to the 1968 H3N2 subtype virus (Figure). For all pandemic viruses, there was no significant difference in seroprevalence by sex or by US birth and only minor differences by race/ethnicity (online Technical Appendix Table 1).

We examined A(H1N1)pdm09 virus seroprevalence by the age of persons tested and by antibody titer. The mean age for persons with no serologic evidence of prior exposure (titer <20) was 50 years, compared with 72 years for those with titers of 20–40 and 80 years for those with titers >40 (online Technical Appendix Table 2). In a multivariate logistic regression model, presence of antibody to the 1918 H1N1 subtype virus was strongly associated with antibody to A(H1N1)pdm09 virus (online Technical Appendix Table 3). No demographic factor was independently associated with positivity to A(H1N1)pdm09 virus. By using a nonlinear regression model for the probability of A(H1N1)pdm09 antibody prevalence compared with birth year, we found the model that best fit the age-stratified seroprevalence data inflected near 1927 (online Technical Appendix Figure), indicating that persons born before 1927 were most reliably protected.

Our findings show that the prevalence of pandemic influenza virus antibody in a representative population-based 2004 sample of NYC residents correlated with birth year and year(s) of circulating virus. These data reveal the immunologic background during the emergence of A(H1N1)pdm09 virus in NYC beginning in late April 2009 (7) and help explain why fewer cases of A(H1N1)pdm09 infection were detected among older persons than younger persons, supporting the conclusion that the difference was a result of, at least in part, antibodies elicited by prior H1N1 subtype infection in older persons.

Viruses antigenically resembling the 1918 pandemic strain circulated among humans earlier in the twentieth century; cross-reactivity with antibodies to those viruses likely provided protection against the 1918 virus. Most (2,4), but not all (8), previous A(H1N1)pdm09 virus seroprevalence studies demonstrated an increase in immunity with age. In our study, more persons born before than after 1927 (i.e., persons >82 vs. those 65–82 years of age in 2009) had HAI assay results positive for A(H1N1)pdm09 virus. Protection among persons 65–82 years old during the 2009 pandemic may be explained by the presence of preexisting immunity not measured by standard HAI tests (e.g., antibodies that target the hemagglutinin stalk) or by T-cell responses (9). More positive test results were recorded with the 1918 than the A(H1N1)pdm09 virus; this finding is consistent with the model in which preexisting immunity to A(H1N1)pdm09 virus was derived from exposure to the 1918 pandemic strain or to antigenically related strains that evolved since then (10). The 1918 and 2009 strains used in testing may have exhibited different sensitivities in HAI assays. Immunity in older populations is not surprising and was seen in the 1918, 1957, and 1968 pandemics, during which newly introduced pandemic viruses were more likely to cause clinical illness in younger persons, presumably because prior exposure to similar viruses resulted in cross-reactive antibodies (11).

Study limitations include a relatively small sample size and a lack of history regarding influenza virus infection or vaccination. Nevertheless, the ability to evaluate seroreactivity in a representative sample of adults helps validate and reinforce previously published findings on H1N1 subtype viruses and clarifies levels of immunity to H2N2 and H3N2 subtype viruses.

Figure. Seroprevalence of cross-reactive antibodies to the 1918, 1957, 1968, and 2009 pandemic influenza viruses among persons >23 years of age, New York, New York, 2004. LOESS (locally weighted scatterplot smoothing) curves represent the estimated prevalence of hemagglutination-inhibition antibody titers of ≥40 (positive titers) by year of birth.

**Isaac B. Weisfuse,
Tshidi Tsibane, Kevin J. Konty,
Joseph R. Egger,[1]
Elizabeth Needham Waddell,
Saad Rahmat, Emily Harris,
Donald R. Olson,
and Christopher F. Basler**

Author affiliations: New York City Department of Health and Mental Hygiene, New York, New York, USA (I.B. Weisfuse, K.J. Konty, J.R. Egger, E.N. Wadell, D.R. Olson); Mount Sinai School of Medicine, New York (T. Tsibane, S. Rahmat, E. Harris, C.F. Basler); and International Society for Disease Surveillance, New York, (D.R. Olson)

References

1. Jhung MA, Swerdlow D, Olsen SJ, Jernigan D, Biggerstaff M, Kamimoto L, et al. Epidemiology of 2009 pandemic influenza A (H1N1) in the United States. Clin Infect Dis. 2011;52(Suppl 1):S13–26. http://dx.doi.org/10.1093/cid/ciq008
2. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature. 2009;460:1021–5.
3. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;360:2605–15. http://dx.doi.org/10.1056/NEJMoa0903810
4. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009;361:1945–52. http://dx.doi.org/10.1056/NEJMoa0906453
5. McCullers JA, Van De Velde LA, Allison KJ, Branum KC, Webby RJ, Flynn PM. Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus. Clin Infect Dis. 2010;50:1487–92. http://dx.doi.org/10.1086/652441
6. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science. 2009;325:197–201. http://dx.doi.org/10.1126/science.1176225
7. Lessler J, Reich NG, Cummings DAT; New York City Department of Health and Mental Hygiene Swine Flu Investigation Team. Outbreak of 2009 pandemic influenza A (H1N1) at a New York City school. N Engl J Med. 2009;361:2628–36. http://dx.doi.org/10.1056/NEJMoa0906089
8. Chen H, Wang Y, Liu W, Zhang J, Dong B, Fan X, et al. Serologic survey of pandemic (H1N1) 2009 virus, Guangxi Province, China. Emerg Infect Dis. 2009;15:1849–50.
9. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med. 2011;208:181–93. http://dx.doi.org/10.1084/jem.20101352
10. Zimmer SM, Crevar CJ, Carter DM, Stark JH, Giles BM, Zimmerman RK, et al. Seroprevalence following the second wave of pandemic 2009 H1N1 influenza in Pittsburgh, PA, USA. PLoS ONE. 2010;5:e11601. http://dx.doi.org/10.1371/journal.pone.0011601
11. Dowdle WR. Influenza A virus recycling revisited. Bull World Health Organ. 1999;77:820–8.

Address for correspondence: Kevin J. Konty, New York City Department of Health and Mental Hygiene, Gotham Center, 42-09 28th St, Long Island City, New York 10471, USA; email: kkonty@health.nyc.gov

Letters

Letters commenting on recent articles as well as letters reporting cases, outbreaks, or original research are welcome. Letters commenting on articles should contain no more than 300 words and 5 references; they are more likely to be published if submitted within 4 weeks of the original article's publication. Letters reporting cases, outbreaks, or original research should contain no more than 800 words and 10 references. They may have 1 Figure or Table and should not be divided into sections. All letters should contain material not previously published and include a word count.

Pulmonary *Streptomyces* Infection in Patient with Sarcoidosis, France, 2012

To the Editor: *Streptomyces* spp. are aerobic, gram-positive bacteria of the order Actinomycetales, known for their ability to produce antimicrobial molecules such as streptomycin. *Streptomyces* spp., usually saprophytic to humans, can cause local cutaneous fistulized nodules known as actinomycetoma or mycetoma. Severe invasive infections have seldom been reported, but most cases reported have occurred in immunocompromised patients (*1–5*). We report a case of invasive pulmonary infection caused by a *Streptomyces* sp. in a splenectomized patient with sarcoidosis.

In 2003, multiorgan sarcoidosis was diagnosed in a man, 57 years of age; the disease involved lungs, skin, joints, and lymph nodes. Corticosteroids were initially given but quickly discontinued because of a severe psychiatric reaction. In 2007, a splenectomy was performed on this patient to remove an intestinal obstruction caused by a severely enlarged spleen, identified as a specific localization of sarcoidosis.

In April 2008, the patient was admitted to the internal medicine unit of Saint-André Hospital in Bordeaux, France with fever (38.9°C/102°F), progressive asthenia, anorexia, weight loss, productive cough, and New York Heart Association grade III dyspnea. Bilateral basal crackles could be heard in the lungs; physical examination findings were otherwise within normal limits. Biological tests showed inflammatory syndrome with elevated C-reactive protein (74 mg/L, reference value <5 mg/L) without any other consequential abnormality. Gamma globulin levels were normal. A chest radiograph showed bilateral interstitial infiltrate. A computed tomogra-

Seroprevalence of Pandemic Influenza Viruses, New York, New York, USA, 2004

Technical Appendix

The New York City Health and Nutrition Examination Survey (NYC HANES) was a population based sample of New York City adults collected in 2004. To determine seroprevalence to 2009 H1N1 antibody, as well as viruses from prior pandemics, a 400 person subsample of repository serum was selected for inclusion in the study, representing persons who were 23 or older in 2004. All specimens were tested by hemagglutination inhibition assays for 1918 H1N1, 1957 H2N2, 1968 H3N2, and 2009 H1N1 pandemic influenza viruses.

Datasets and Methods

NYC Health and Nutrition Examination Survey

In 2004, the New York City Department of Health and Mental Hygiene (NYCDOHMH) conducted a population-based, cross sectional survey of NYC adults modeled after the National Health and Nutrition Examination Survey (HANES). The methodology for NYC HANES has been described in detail elsewhere (1). In brief, the survey population included a representative sample of non-institutionalized adults, ages 20 and older, recruited through letters and field visits, followed up by interviews, physical examination and biologic specimen collection for consenting participants. A 3-stage cluster sampling plan was used to recruit participants between June and December 2004. The stages of sample selection were as follows: 1) selection of census blocks or groups of blocks; 2) random selection of households within selected segments; and 3) random selection of study participants within households. The survey included a face-to-face computer-assisted personal interview, private audio computer-assisted self-interview, physical examination, and laboratory testing (sera and urine). The overall response rate was 55%. Participants were asked to consent to allow for collection and storage of additional biologic samples for future research purposes, without notification of the results. Demographic data

collected at the time of interview included age, race/ethnicity, country of birth, and gender. Occupational and influenza histories were not collected.

Specimen Sampling

From the specimen repository we randomly selected serum samples from those persons born in 1981 or earlier (persons age 23 or older at the time of the NYC HANES collection) to include in this study. This would allow us to better understand prior exposure to H1N1 (presumably conferring immunity), which might explain the age-related pattern of illness seen during the 2009 H1N1 pandemic in New York City and elsewhere. Other objectives were to understand the patterns of measurable neutralizing antibody titers to the 1918 H1N1, 1957 H2N2, and 1968 H3N2 pandemic influenza viruses.

The total sample size of NYC HANES was 1,999. Of these, 1,811 completed the serosurvey component. Serum specimens were collected from most consenting participants and are stored at the NYCDOHMH's Public Health Laboratory at –70°C. From these, a subsample of 400 was selected for testing. The data were weighted to adjust for the complex sampling, design nonresponse, and post-stratification. The weights were further adjusted to address component- and item- nonresponse

The subsample was drawn in such a way as to address two distinct purposes of the study. The first was to establish a cutoff birth date, before which individuals may show an increased likelihood of cross-reactivity to the 2009 H1N1 virus . The second was to estimate the level of cross-reactive antibodies for those born before the cutoff. The first purpose favors selecting more samples around the potential cutoff while the second favors selecting sample from respondents born before the cutoff. After establishing a potential range for the cutoff value, the sample was drawn with increasing probability in the range, very low probability below the range, and moderate probability above the range. Component weights were adjusted by their inverse probability of selection into the subsample and then scaled to the population total.

Laboratory Testing

Human Sera Treatment:

Human sera was treated with trypsin periodate, according to established procedures, to remove nonspecific inhibitors of hemagglutination (*2*).

Virus and Virus like particle (VLP) production:

The 1918 pandemic H1N1 and 1957 pandemic H2N2 viruses were assayed using non-infectious virus-like particles (VLPs) rather than live virus to allow for use at biosafety level 1 (BSL1). In brief, VLPs were produced by co-transfecting HEK293T cells with expression plasmids encoding the hemagglutinin (HA) and neuraminidase (NA) corresponding to influenza A/South Carolina/1/18 (H1N1) virus, influenza A/Singapore/1/57 (H2N2) virus or influenza A/Japan/305/57 (H2N2) virus. Supernatants from the transfected cells were harvested 48 hours later, aliquoted and stored at −20°C until use (3).

For the pandemic 2009 (H1N1) virus, we utilized a 6:2 PR8 recombinant virus, with the HA and NA of A/California/4/2009 (H1N1) and 6 internal genes from influenza A/Puerto Rico/8/1934 (H1N1) virus (5). This recombinant virus was propagated at 37°C in MDCK cells and could be used at BSL 2 level. The A/HK/1/68 (H3N2) virus was propagated at 37°C in 10 day old embryonated chicken eggs.

Hemagglutination Inhibition (HAI) Assays:

Virus or VLPs were diluted to a concentration of 8–16 HA units/50 mL^3. The diluted virus or VLPs were incubated with serial two-fold dilutions of trypsin periodate-treated human sera for 30 minutes at 4°C, followed by incubation with 0.5% turkey RBCs for the CA/09 virus and 0.5% chicken RBC's for all the other viruses or VLPs. Results were recorded as the reciprocal of the greatest dilution yielding inhibition of hemagglutination (4).

Statistical Analysis

For all analyses a hemagglutination titer of 40 or greater was used to indicate prior exposure and/or immunity to the virus in question. Laboratory data were merged with demographic information including date of birth, age (as of 2004), gender, country of birth (USA vs. foreign born), and race/ethnicity to determine the prevalence of prior exposure by these factors.

Locally weighting smoothing scatterplots (LOESS curves) (5) were used to estimate the prevalence of antibodies by year of birth. To appropriately account for the complex survey design of NYC HANES, logistic regression models were fit using Sudaan version 10.0 (6). Nonlinear models were used to explicitly estimate the cutoff year for increased probability of immunity, using a segmented regression model that includes cutoff year as a parameter (7).

Institutional Review Boards

This study was approved by both the Mount Sinai School of Medicine and NYCDOHMH Institutional Review Boards.

References

1. Thorpe LE, Gwynn RC, Mandel-Ricci J, et al. Study design and participation rates of the New York City Health and Nutrition Survey, 2004. Prev Chronic Dis. 2006;3:1–8.

2. World Health Organization. WHO manual on animal influenza diagnosis and surveillance [cited 2012 Sep 3]. WHO/CDS/CSR/NCS/2002.5Rev.1; p. 37–79. http://www.who.int/csr/resources/publications/influenza/whocdscsrncs20025rev.pdf

3. Yu X Tshidi Tsibane T, Patricia A. McGraw PA, et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature. 2008;455:532–6.

4. Hirst G. K. The quantitative determination of influenza virus and antibodies by means of red cell agglutination. J Exp Med. 1942;75:49–64.

5. Cleveland, WS. Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc. 1979:74:829–36.

6. Research Triangle International. Research Triangle Park, North Carolina.

7. Muggeo VMR. Estimating regression models with unknown break-points. Stat Med. 2003; 22:3055-71.

Technical Appendix Table 1. Weighted seroprevalence of cross-reactive antibodies to the 1918, 1957, 1968, and 2009 pandemic influenza viruses among persons >23 years of age, New York, New York, USA, 2004*

Characteristic	Total No.	H1N1 (1918)			H2N2 (1957)			H3N2 (1968)			H1N1(2009)		
		No. +	Prev (%)	95% CI	No. +	Prev (%)	95% CI	No. +	Prev (%)	95% CI	No. +	Prev (%)	95% CI
Total	400	24	10.1	6.8–14.8	93	24.2	19.3–29.9	278	72.1	66.9–76.9	17	6.6	4.1–10.4
Age, y													
23–27	31	1	9.4	0.4–17.7	1	1.6	0.2–29.7	10	30.2	16.3–49.1	1	2.8	0.4–17.7
28–32	47	1	5.5	0.2–10.6	3	7.1	2.0–30.3	12	27.0	15.6–42.5	0	0	—
33–37	46	2	3.8	0.9–15.4	1	3.1	0.4–18.5	38	83.0	67.8–91.9	1	2.8	0.4–16.8
38–42	49	0	0	—	2	5.2	1.3–47.8	44	90.9	79.4–96.3	0	0	---
43–47	41	0	0	—	15	40.4	25.6–77.6	36	90.7	76.5–96.7	1	2.6	0.4–17.1
48–52	42	0	0	—	23	59.2	42.0–87.2	37	90.5	78.3–96.1	0	0	—
53–57	35	0	0	—	19	52.5	35.5–89.2	27	79.2	62.0–89.8	1	1.8	0.2–11.6
58–62	26	1	4.8	0.6–28.2	11	42.3	21.7–86.1	21	78.2	53.9–91.7	1	4.8	0.6–28.2
63–67	20	0	0	—	8	37.5	18.2–67.5	13	63.1	36.4–83.6	0	0	—
68–72	14	1	3.3	0.5–18.4	3	15.7	5.2–56.8	9	68.2	43.5–85.6	1	3.3	0.5–18.4
73–77	22	4	20.5	7.5–45.0	3	12.3	3.7–45.1	16	73.5	49.5–88.7	1	4.7	0.6–27.4
78–82	15	8	55.3	31.6–76.8	2	13.8	2.9–65.7	8	60.2	30.5–83.9	3	18.0	5.1–47.1
83–89	12	6	48.5	23.0–74.9	2	19.5	4.8–61.5	7	73.9	41.3–91.9	7	54.2	27.0–79.2
Total for persons ≥65	75	19	29.9	20.1–42.1	15	17.3	10.0–28.5	49	69.4	57.7–79.1	12	17.8	10.3–29.1
Sex													
Male	182	17	14.0	8.6–22.0	44	25.5	18.5–34.2	121	70.2	62.6–76.9	13	10.8	6.4–17.8
Female	218	7	16.3	2.8–13.3	49	22.9	17.0–30.1	157	74.0	66.6–80.3	4	2.3	0.7–7.4
Country of birth													
United States	214	14	11.1	6.6–18.0	55	26.2	19.2–34.5	151	72.5	65.3–78.6	11	7.7	4.2–13.4
Foreign	185	10	8.8	4.5–16.7	38	21.5	15.4–29.2	127	71.9	64.5–78.3	6	5.1	2.2–11.6
Race/Ethnicity													
Non-Hispanic white	147	8	7.8	3.9–14.9	41	28.2	19.8–38.5	120	70.5	61.6–78.0	6	6.0	2.7–12.7
Non-Hispanic black	94	7	14.2	7.0–26.8	24	26.5	18.2–36.9	85	812.	72.5–87.7	5	8.7	3.4–20.6
Non-Hispanic Asian	45	0	0	0	12	23.7	13.7–37.8	38	69.1	52.7–81.8	1	1.7	0.3–10.1
Hispanic	105	9	16.1	8.4–28.7	14	11.5	6.8–18.7	93	66.6	55.4–76.2	5	8.3	3.4–18.9
Non-Hispanic other	8	0	0	—	2	28.1	6.9–67.1	7	68.7	29.8–91.9	0	—	—
Missing	1												

*Prev, prevalence; +, positive; —, no value.

Table 2. Characteristics of persons with different antibody titers to influenza A(H1N1)pdm09 virus, New York, New York, USA, 2004

Characteristic	Titer		
	<20 (n = 362)	20–40 (n = 29)	>40 (n = 9)
Mean age, y	50	72	80
Median age, y	48	79	85
Male, %	48.7	50.3	75.1
US born, %	55.0	74.5	81.3
Hispanic, %	18.4	20.3	27.6

Table 3. Logistic regression parameter estimates for predicted probability of A(H1N1)pdm09 cross reactivity, New York, New York, USA, 2004*

Parameter	Odds ratio	Standard error	95% CI	z score	p value
Intercept	0.002	1.58	–9.31 to -3.12	-3.94	<0.0001
1918 result (positive)	37.317	1.14	1.39–5.85	3.19	0.001
1919 result (negative)	REF	—	—	—	—
Race/ethnicity					
Hispanic	0.843	1.04	–2.22 to1.87	-0.16	0.870
Non-Hispanic Asian	1.709	1.24	–1.89 to 2.96	0.43	0.665
Non-Hispanic black	1.087	0.97	–1.83 to 1.99	0.09	0.932
Non-Hispanic white	REF	—	—	—	—
Country of birth					
US born	1.893	0.80	–0.93 to 2.21	0.79	0.427
Foreign born	REF	—	—	—	—
Year of birth					
1915–1932	2.942	1.10	–1.09 to 3.24	0.98	0.329
1933–1956	1.314	0.77	–1.24 to 1.79	0.35	0.724
1957–1980	REF	—	—	—	—
Sex					
Female	5.081	0.91	–0.15 to 3.41	1,79	0.074
Male	REF	—	—	—	—

*Model treats year of birth as categorical. REF, referent.

Figure. Predicted probability of cross-reactivity to the influenza A(H1N1)pdm09 virus among persons >23 years of age, New York, New York, USA, 2004. Using a nonlinear regression for the probability of antibody prevalence compared with year of birth, we found that the model that best fits the age-stratified seroprevalence data inflects near birth year of 1927, suggesting a cut-off point for immunity as measured by hemagglutination inhibition assay estimated as July 3, 1927, (95% confidence limits: May 2, 1925, September 3, 1929), and for those after, there is little detectable immunity.